A detailed history of Envestnet Asset Management Inc transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 120,256 shares of SWTX stock, worth $4.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
120,256
Previous 112,426 6.96%
Holding current value
$4.62 Million
Previous $4.24 Million 9.02%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$32.04 - $42.76 $250,873 - $334,810
7,830 Added 6.96%
120,256 $3.85 Million
Q2 2024

Aug 08, 2024

BUY
$36.06 - $47.62 $1.47 Million - $1.94 Million
40,781 Added 56.92%
112,426 $4.24 Million
Q1 2024

May 13, 2024

BUY
$36.5 - $52.5 $201,407 - $289,695
5,518 Added 8.34%
71,645 $3.53 Million
Q4 2023

Feb 13, 2024

BUY
$18.94 - $37.24 $90,533 - $178,007
4,780 Added 7.79%
66,127 $2.41 Million
Q3 2023

Nov 13, 2023

BUY
$23.12 - $31.38 $922,534 - $1.25 Million
39,902 Added 186.07%
61,347 $1.42 Million
Q2 2023

Aug 04, 2023

BUY
$23.15 - $32.71 $125,727 - $177,648
5,431 Added 33.91%
21,445 $562,000
Q1 2023

May 11, 2023

BUY
$24.97 - $34.05 $113,313 - $154,518
4,538 Added 39.54%
16,014 $412,000
Q4 2022

Feb 07, 2023

SELL
$21.73 - $28.72 $63,560 - $84,006
-2,925 Reduced 20.31%
11,476 $298,000
Q3 2022

Nov 10, 2022

BUY
$24.1 - $39.66 $13,447 - $22,130
558 Added 4.03%
14,401 $411,000
Q2 2022

Aug 03, 2022

SELL
$18.36 - $60.07 $46,873 - $153,358
-2,553 Reduced 15.57%
13,843 $341,000
Q1 2022

May 04, 2022

BUY
$48.97 - $65.46 $282,214 - $377,245
5,763 Added 54.2%
16,396 $925,000
Q4 2021

Feb 04, 2022

BUY
$53.3 - $75.84 $144,176 - $205,147
2,705 Added 34.12%
10,633 $659,000
Q3 2021

Oct 07, 2021

BUY
$62.66 - $88.26 $496,768 - $699,725
7,928 New
7,928 $503,000

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.4B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.